MARCH 29, 2021 — The Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium today announced the U.S. Department of Energy’s Argonne, Brookhaven and Oak Ridge national laboratories are joining the consortium to further develop ATOM’s artificial intelligence (AI)-driven drug discovery platform. The public-private ATOM consortium aims to transform drug discovery from a slow, sequential and high-risk process […]
Video: ATOM Consortium to Accelerate AI in Drug Discovery with NVIDIA
April 8, 2019 by
The Public-private consortium ATOM has announced today that it is collaborating with NVIDIA to scale ATOM’s AI-driven drug discovery platform. “Scientists at ATOM have created a predictive model development pipeline that calls upon large datasets to build and test predictive machine learning models which consider pharmacokinetics, safety, developability, and efficacy. NVIDIA will provide additional resources that will enable this pipeline to be run at increased scale and speed.”
